Liabilities Breakdown
| Total Liabilities | 26.99 Million | |
| Current Liabilities | 24.2 Million | |
| Long-Term Liabilities | 209,676 |
How much will Bionano Genomics owe in February?
 | By Rifka Kats | Macroaxis Story |
The upcoming quarterly report is expected on the 9th of March 2021. The stock is still going through an active upward rally. Bionano Genomics Book Value per Share is quite stable at the moment as compared to the past year. The company's current value of Book Value per Share is estimated at 0.30. Current Ratio is expected to rise to 1.76 this year, although the value of Average Assets will most likely fall to about 26.6 M. As many millenniums are trying to avoid healthcare space, it makes sense to outline Bionano Genomics a little further and try to understand its current market patterns. I will address a few possible reasons institutional investors do not currently respect this stock.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Vlad Skutelnik
Bionano Genomics currently holds 16.01 M in liabilities with Debt to Equity (D/E) ratio of 1.09, which is about average as compared to similar companies. This firm has a current ratio of 1.16, suggesting that it is in a questionable position to pay out its financial obligations when due. Bionano Genomics financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Bionano Genomics, including all of Bionano Genomics's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Bionano Genomics assets, the company is considered highly leveraged. Understanding the composition and structure of overall Bionano Genomics debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.
Watch out for price decline
Please consider monitoring Bionano Genomics on a daily basis if you are holding a position in it. Bionano Genomics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Bionano Genomics stock to be traded above the $1 level to remain listed. If Bionano Genomics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Understanding Bionano Total Debt
Bionano Genomics liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Bionano Genomics has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Bionano Genomics balance sheet include debt obligations and money owed to different Bionano Genomics vendors, workers, and loan providers. Below is the chart of Bionano main long-term debt accounts currently reported on its balance sheet. You can use Bionano Genomics financial leverage analysis tool to get a better grip on understanding its financial positionHow important is Bionano Genomics's Liquidity
Bionano Genomics financial leverage refers to using borrowed capital as a funding source to finance Bionano Genomics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Bionano Genomics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Bionano Genomics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Bionano Genomics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Bionano Genomics's total debt and its cash.
What is driving Bionano Genomics Investor Appetite?
The company reported the previous year's revenue of 7.3 M. Net Loss for the year was (37.28 M) with profit before overhead, payroll, taxes, and interest of 3.36 M.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Bionano Genomics. Please refer to our Terms of Use for any information regarding our disclosure principles.